Procter & Gamble Health Ltd
P&G Health Ltd (formerly Procter & Gamble td) (erstwhile Merck Limited) is engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.[1]
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Dec 2014 | Dec 2015 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Injectable Production Capacity (Goa Plant) Million units per annum ・Standalone data |
|
||||||||
| Total Employees Number ・Standalone data |
|||||||||
| Healthcare Practitioners (HCPs) Engaged Number ・Standalone data |
|||||||||
| Direct Rural Reach Number of towns ・Standalone data |
|||||||||
| Pharmacy Reach (Neurobion) Number of stores ・Standalone data |
|||||||||
| Total Pharmacy Reach Number of stores ・Standalone data |
|||||||||
| Total Retail Outlet Coverage Number of outlets ・Standalone data |
|||||||||
| Productivity Savings INR Crores ・Standalone data |
|||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||
Documents
Announcements
-
Board Meeting Intimation for Intimation Of Board Meeting
27 Mar - Board meeting on May 26, 2026 to approve FY2026 audited statements and consider final dividend.
- Closure of Trading Window 27 Mar
-
Communication In Respect Of Deduction Of Tax At Source (TDS) On The Amount Of Dividend Income From Procter & Gamble Health Limited
6 Feb - Interim dividend Rs.160/share (incl. Rs.50 special); record date Feb 12, 2026; TDS guidance and Feb 10 document deadline
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 Feb - Q3 sales ₹368 crore (+21%), PAT ₹78 crore; interim dividend ₹160/share (₹50 special).
- Record Date 6 Feb
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
Concalls
-
Jun 2025Transcript PPT
-
Dec 2023TranscriptAI SummaryPPT
-
Nov 2022TranscriptAI SummaryPPT
-
May 2018TranscriptAI SummaryPPT
Strong Brand Portfolio
Company is one the India’s largest VMS companies, manufacturing and marketing vitamins, minerals and supplements. It has a strong portfolio of various pharma brands such as Evion, Neurobion, Seven seas, Nasivion, Polybion, Cosome and Livogen. [1]